| human | Q5 |
| P69 | educated at | Heidelberg University Faculty of Medicine in Mannheim | Q5698722 |
| P734 | family name | Marmé | Q109533509 |
| Marmé | Q109533509 | ||
| Marmé | Q109533509 | ||
| P735 | given name | Frederik | Q17539077 |
| Frederik | Q17539077 | ||
| P106 | occupation | researcher | Q1650915 |
| Q92898068 | 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q92609057 | A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial |
| Q96950984 | A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer |
| Q48170092 | A low-frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<60 years) and is associated with reduced DNA repair capacity |
| Q35674616 | A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). |
| Q92389245 | A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA) |
| Q30315301 | ABC3 Consensus: Assessment by a German Group of Experts |
| Q90318514 | ASCO 2019: New Results in Breast Cancer |
| Q53068698 | Aesthetic and functional results after breast conserving surgery as correlates of quality of life measured by a German version of the Breast Cancer Treatment Outcome Scale (BCTOS). |
| Q36073563 | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression |
| Q91287008 | Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial |
| Q37057992 | Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers |
| Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
| Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
| Q40870110 | BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial |
| Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q92035335 | Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial |
| Q39063417 | Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q53675136 | Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy. |
| Q39465495 | CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer |
| Q85893100 | CD24 polymorphisms in breast cancer: impact on prognosis and risk |
| Q52838631 | CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer. |
| Q36449203 | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer |
| Q91748658 | COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer |
| Q28385765 | Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk |
| Q92824108 | Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial |
| Q36279137 | Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer |
| Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
| Q57191514 | DNA methylation array analyses identified breast cancer-associatedHYAL2methylation in peripheral blood |
| Q37665624 | DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA. |
| Q93065168 | Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883) |
| Q90315301 | Design and development of 99mTc labeled FAPI-tracers for SPECT-imaging and 188Re therapy |
| Q44234056 | Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients |
| Q92235904 | Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention |
| Q91450129 | Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial |
| Q38857412 | Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). |
| Q61970360 | Doxorubicin/Pemetrexed Followed by Docetaxel Versus Doxorubicin/Cyclophosphamide Followed by Docetaxel as Neoadjuvant Treatment for Early-Stage Breast Cancer: A Randomized Phase II Trial |
| Q56967384 | Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer etc. |
| Q33411565 | Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer |
| Q85905410 | Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
| Q91559123 | Extracapsular Lymph Node Involvement in Ovarian Carcinoma |
| Q92439276 | Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer |
| Q61853672 | Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer |
| Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q35063160 | Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk |
| Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
| Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
| Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
| Q53291654 | Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q36422109 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium |
| Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q91910743 | Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy |
| Q36153347 | Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q39162225 | Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q57114269 | Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies |
| Q38853661 | Immunotherapy in Breast Cancer |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q42638892 | Invasive ductal breast cancer within a malignant phyllodes tumor: case report and assessment of clonality |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q93006343 | Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score |
| Q39949768 | Loss of Drop1 expression already at early tumor stages in a wide range of human carcinomas |
| Q53246437 | Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage. |
| Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
| Q91669222 | Luminal Metastatic Breast Cancer |
| Q35938054 | Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications |
| Q90285508 | Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient |
| Q89056459 | Molecular Tumor Boards |
| Q39721191 | Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q38125184 | Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice |
| Q30588206 | Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials |
| Q90093959 | Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q92086589 | Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer |
| Q44822009 | Omission of axillary dissection according to ACOSOG Z0011: impact on adjuvant treatment recommendations |
| Q48030360 | Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials |
| Q39658722 | Personalized therapy in breast cancer |
| Q39749362 | Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial |
| Q52809433 | Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors. |
| Q48212691 | Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. |
| Q40768670 | Plasma S100P level as a novel prognostic marker of metastatic breast cancer |
| Q41035419 | Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer |
| Q35032320 | Plasma microRNA panel for minimally invasive detection of breast cancer |
| Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
| Q61795635 | Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q61805469 | Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index |
| Q94549758 | Prediction of pathological complete response in breast cancer patients during neoadjuvant chemotherapy: Is shear wave elastography a useful tool in clinical routine? |
| Q47999823 | Predictors of Residual Tumor in Breast-Conserving Therapy |
| Q51331347 | Predictors of resectability in breast-conserving therapy. |
| Q46343091 | Preeclampsia: increased expression of soluble ADAM 12. |
| Q46567658 | Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). |
| Q36135274 | Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study |
| Q91669194 | Prophylaxis and Management of Skin Toxicities |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q43728324 | Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q91922652 | Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study |
| Q52805932 | Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinico-molecular predictor. |
| Q36545934 | SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival |
| Q90115519 | Second breast conserving therapy after ipsilateral breast tumor recurrence - a 10-year experience of re-irradiation |
| Q34485182 | Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients |
| Q48305630 | Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine |
| Q57053023 | Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer |
| Q39888415 | Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes |
| Q33425044 | T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. |
| Q90655152 | TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer |
| Q90728585 | TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer |
| Q26777736 | Targeted Therapies in Triple-Negative Breast Cancer |
| Q41934943 | The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer. |
| Q40234422 | The association between breast cancer and S100P methylation in peripheral blood by multicenter case-control studies |
| Q35000396 | The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns |
| Q33730051 | The impact of human adipose tissue-derived stem cells on breast cancer cells: implications for cell-assisted lipotransfers in breast reconstruction |
| Q90262550 | The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial |
| Q53127630 | The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. |
| Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
| Q93164318 | Use of Taxanes in Metastatic HER2-negative Breast Cancer - a Status Report |
| Q41029345 | Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy |
| Q58100774 | What is the evidence for lymphadenectomy in presumed early ovarian cancer? |
| Q91923116 | Preclinical evaluation of peptide-based radiotracers for integrin αvβ6-positive pancreatic carcinoma |
Search more.